New hope for rare fat disorder: experimental drug mibavademab under safety review
NCT ID NCT06548100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety of switching from the current drug metreleptin to a new experimental drug called mibavademab in people with generalized lipodystrophy, a rare condition where the body cannot properly store fat. Nine participants who have been stable on metreleptin will receive mibavademab and be monitored for side effects, blood levels, and how their body responds. The goal is to see if this new drug is a safe alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mibavademab (also called REGN4461), a leptin receptor agonist antibody
What this could lead to
If successful, mibavademab could offer a new treatment option for generalized lipodystrophy, potentially replacing the current therapy metreleptin.
What could go wrong
This is a very small early-phase safety study with only 9 participants, so results may not apply to everyone. The drug may cause side effects or not work as well as the current treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States